Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

NCT ID: NCT04979923

Last Updated: 2021-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Acute Respiratory Distress Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine group

Group Type EXPERIMENTAL

Lidocaine

Intervention Type DRUG

Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Salbutamol group

Group Type PLACEBO_COMPARATOR

Lidocaine

Intervention Type DRUG

Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Beclomethasone plus salbutamol

Group Type ACTIVE_COMPARATOR

Lidocaine

Intervention Type DRUG

Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Covid-19 positive
* Moderate to severe ARDS

Exclusion Criteria

* patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheikh Zayed Medical College

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sairah Sadaf

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sheikh zayed medical college & hospital

Rahim Yar Khan, Punjab Province, Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

sairah s sadaf, FCPS

Role: CONTACT

0092 689230165 ext. 245

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

alina a umar, MCPS

Role: primary

0092 689230165 ext. 245

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

227/IRB/SZMC/SZH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug Study of Albuterol to Treat Acute Lung Injury
NCT00434993 TERMINATED PHASE2/PHASE3
Role of Salbutamol and Furosemide in TTN
NCT03208894 COMPLETED PHASE3
Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension
NCT06249633 NOT_YET_RECRUITING EARLY_PHASE1